Log In
BCIQ
Print this Print this
 

ZX007

  Manage Alerts
Collapse Summary General Information
Company Pernix Therapeutics Holdings Inc.
DescriptionAbuse-deterrent tablet formulation of extended-release hydrocodone
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat moderate to severe chronic pain
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$383.5M

$30.0M

$283.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/10/2015

$383.5M

$30.0M

$283.5M

Get a free BioCentury trial today